Neoadjuvant Strategies: Locally Advanced Rectal Cancer

Abstract

Colorectal cancer is one of the major leading causes of death in both men and women. The successful management of colon or rectal cancer demands a multidisciplinary approach. In the last few years, significant improvement has been noticed in the management of localized rectal cancer to reduce local recurrence and obtain complete pathological response following appropriate surgical steps, if necessary. Implementation of neoadjuvant therapy not only enhances disease control, it may also ensure sphincter preserving procedures or organ-preserving options. This article principally concentrates on the current neoadjuvant treatment for locally advanced rectal cancer and the prognostic outcomes of such therapy, including a discussion on the historical perspective.

Keywords

colorectal cancer - rectal cancer - neoadjuvant chemoradiation - adjuvant chemotherapy - survival

• References

• 1 Society AC. . Cancer Facts and Figures 2016. 2016 ; Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
• 2 Dewdney A, Cunningham D, Chau I. Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. Oncologist 2013; 18 (07) 833-842
• 3 Chang JS, Lee Y, Lim JS. , et al. The magnetic resonance imaging-based approach for identification of high-risk patients with upper rectal cancer. Ann Surg 2014; 260 (02) 293-298
• 4 Taylor FG, Quirke P, Heald RJ. , et al; MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253 (04) 711-719
• 5 Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358 (9290): 1291-1304
• 6 Kapiteijn E, Marijnen CA, Nagtegaal ID. , et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
• 7 van Gijn W, Marijnen CA, Nagtegaal ID. , et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12 (06) 575-582
• 8 Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23 (24) 5644-5650
• 9 Ngan SY, Burmeister B, Fisher RJ. , et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30 (31) 3827-3833
• 10 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
• 11 Chen C, Sun P, Rong J, Weng HW, Dai QS, Ye S. Short course radiation in the treatment of localized rectal cancer: a systematic review and meta-analysis. Sci Rep 2015; 5: 10953
• 12 Mohiuddin M, Regine WF, John WJ. , et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000; 46 (04) 883-888
• 13 Fisher B, Wolmark N, Rockette H. , et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80 (01) 21-29
• 14 Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3 (03) CD004078
• 15 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955): 939-944
• 16 Kotake T. Clinical problems in patients who were exposed to carcinogens [article in Japanese]. Hinyokika Kiyo 1989; 35 (12) 2063-2067
• 17 Hong YS, Nam BH, Kim KP. , et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15 (11) 1245-1253
• 18 Bosset JF, Calais G, Mineur L. , et al; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15 (02) 184-190
• 19 Glynne-Jones R, Counsell N, Quirke P. , et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014; 25 (07) 1356-1362
• 20 Breugom AJ, van Gijn W, Muller EW. , et al; Cooperative Investigators of Dutch Colorectal Cancer Group and Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015; 26 (04) 696-701